Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 38
- Registration Number
- NCT03081481
- Locations
- ๐บ๐ธ
Chesapeake Urology Associates, Baltimore, Maryland, United States
๐ฌ๐งImperial College, London, United Kingdom
๐บ๐ธNew York Urology Associates, New York, New York, United States
Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 18
- Registration Number
- NCT02499848
- Locations
- ๐ฌ๐ง
UCLH, London, United Kingdom
Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2017-04-27
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 479
- Registration Number
- NCT01966614
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2013-08-21
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 40
- Registration Number
- NCT01454349
- Locations
- ๐บ๐ธ
Atlantic Urology Medical Group, Long Beach, California, United States
๐บ๐ธThe Iowa Clinic, West Des Moines, Iowa, United States
๐บ๐ธAccumed Research Associates, Garden City, New York, United States
Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 92
- Registration Number
- NCT00889707
- Locations
- ๐จ๐ฆ
The Fe/Male Health Centers, Oakville, Ontario, Canada
๐จ๐ฆBrantford Urology Research, Brantford, Ontario, Canada
๐จ๐ฆUrology Associates / Urology Medical Research, Kitchener, Ontario, Canada
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Sophiris Bio Corp
- Registration Number
- NCT00797940
An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy
- Conditions
- Locally Recurrent Prostate Cancer
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2009-10-29
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 30
- Registration Number
- NCT00686088
- Locations
- ๐บ๐ธ
Urology San Antonio, San Antonio, Texas, United States
๐บ๐ธScott & White Memorial Hospital, Temple, Texas, United States
PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: PSA-Activated PSA-PAH1
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- Sophiris Bio Corp
- Target Recruit Count
- 24
- Registration Number
- NCT00379561
- Locations
- ๐บ๐ธ
Cancer Research Institute of Scott and White, Temple, Texas, United States